Aerospace, Energy and Medical: Three Different Paths to Industrial 3D Printing

Additive manufacturing companies often describe their target markets in a single breath: aerospace, energy and medical. The three share obvious features. All value high-performance materials. All pay a premium for complex, low-volume parts. All have produced well-publicised AM success stories.

But from the perspective of a manufacturer deciding where to invest, they are three very different businesses. The value AM creates differs. The qualification path differs. The regulators, customers and standards differ. A capability that has taken years to establish in one sector may count for surprisingly little in the next.

This article compares the three, not to rank them, but to explain why "we've done it in aerospace" is the beginning of a market-entry conversation, not the end of one.

Aerospace: performance per kilogram, proven over time

Where AM creates value

Aerospace AM is driven largely by performance per unit weight and functional consolidation. Removing mass from aircraft and engines has lasting value through fuel consumption, payload and emissions over a long service life. AM allows engineers to design topology-optimised brackets, integrated fluid passages, complex cooling features and consolidated assemblies that conventional machining or casting cannot easily produce.

The most cited example remains the fuel nozzle tip for the CFM LEAP engine, in which GE Aerospace replaced around 20 separately made and joined pieces with one additively manufactured part roughly 25 percent lighter.

Aerospace also uses AM extensively outside flight hardware: tooling, fixtures, prototypes and ground- support equipment, where qualification demands are much lower.

Barriers: qualification, traceability and fatigue

Flight-critical parts face exceptionally demanding requirements. Manufacturers must demonstrate consistent material properties, particularly fatigue performance, which is sensitive to porosity, surface roughness and microstructure, all variables AM can influence. They must also show process stability across builds, machines and powder lots, and maintain full traceability from powder batch to installed part.

The approval chain typically involves the part producer, the engine or airframe OEM and, for certified products, aviation authorities. Specification bodies have developed AM-specific material and process standards, such as SAE's AMS7000-series specifications for laser powder bed fusion. For space hardware, NASA has published dedicated AM requirements in NASA-STD-6030.

Appropriate applications, and limitations

The strongest aerospace cases combine weight reduction, consolidation and moderate production volumes with an OEM willing to invest in qualification. The limitation is time. Qualifying a new AM part for flight can take years, and the economics only work when that effort is spread over a meaningful production run or a high-value capability.

Energy and oil & gas: availability, not lightness

Where AM creates value

Energy applications are driven by a different economic logic: availability. An offshore platform, refinery, LNG plant or power station can lose very large sums for every day a critical asset is out of service. If a

replacement part has a long lead time, or the original supplier no longer makes it, the value of producing a qualified replacement quickly can far exceed the cost of the part.

Typical opportunities include:

• Critical and obsolete spare parts, including impellers, valve components, nozzles and housings for legacy equipment.

• Remote operations, where logistics are slow and expensive.

• Repair and remanufacturing of worn high-value components, often using directed energy deposition or cladding.

• Performance improvements to components such as burner tips, heat exchangers and flow- control parts.

Weight reduction, the dominant aerospace driver, is rarely a priority.

Barriers: environment, certification and operational risk

Energy parts often operate under high pressure, high temperature, corrosive media or sour service, and failure can have serious safety and environmental consequences. Material performance under these conditions must be demonstrated, not assumed.

The sector has developed its own framework. The American Petroleum Institute published API Standard 20S in 2021, setting requirements for additively manufactured metallic components used in the petroleum and natural gas industries. DNV's standard DNV-ST-B203, updated in a 2022 edition, sets out a qualification and production framework for additively manufactured metallic parts in energy and maritime applications. Operators and equipment manufacturers also impose their own technical requirements.

A further complication is reverse engineering. Many spare-parts opportunities involve legacy components for which original drawings or material specifications are incomplete. Producing a part that is dimensionally correct is not the same as producing one that performs equivalently. Intellectual property rights in the original design must also be respected.

Appropriate applications, and limitations

The best energy cases target parts with high downtime cost, long or uncertain conventional lead times and a clear qualification route, often starting with lower-criticality components and building a track record. The limitation is that each part may need its own assessment. The "digital warehouse" concept is attractive, but the qualification effort per part number is real, and many spare-parts catalogues contain thousands of low-demand items.

Medical: personalisation inside a regulated system

Where AM creates value

Medical AM's distinctive advantage is personalisation. AM can produce devices matched to a patient's anatomy from imaging data, and porous structures that support bone ingrowth in orthopaedic implants. Applications include:

• Patient-specific surgical guides and anatomical models for surgical planning.

• Orthopaedic and spinal implants, including standard sizes with porous surfaces and patient- specific designs.

• Dental devices, among the highest-volume medical AM applications.

• Prosthetics and orthotics.

Value here is clinical and operational: better fit, potentially shorter surgical times and devices that would be difficult to manufacture conventionally.

Barriers: biocompatibility, sterilisation, validation and regulation

Medical devices are regulated according to their risk and intended use. In the United States, the FDA's guidance Technical Considerations for Additive Manufactured Medical Devices (final, December 2017) sets out the agency's thinking on design and manufacturing considerations. These include process validation, material controls, post-processing, patient-matched device design and testing. Equivalent regulatory systems apply in other markets, including the EU, Singapore and Australia.

Beyond regulatory submission, medical manufacturers must manage:

• Biocompatibility, typically assessed using the ISO 10993 series, which is affected by material, residual powder, processing aids and cleaning.

• Cleaning and sterilisation validation, which is particularly challenging for porous and lattice structures that can trap powder or contaminants.

• Quality management systems, commonly built around ISO 13485, covering design controls, traceability, supplier control and complaint handling.

• Patient-matched workflows, where imaging, segmentation, design, clinician approval and manufacturing form a controlled, documented chain.

Appropriate applications, and limitations

Medical AM works best where personalisation or porous structures provide a clear clinical or economic benefit within an established regulatory pathway. The limitation is that the manufacturing process is only one part of a medical device business. Regulatory strategy, clinical evidence, reimbursement and relationships with surgeons and hospitals often determine commercial success more than the printing technology itself.

An industry comparison framework

Dimension Aerospace Energy and oil & gas Medical

Primary source of          Weight reduction,          Availability, downtime      Personalisation, porous
value                      consolidation,             avoided, obsolescence       structures, clinical
                           performance                solved                      outcomes

Typical volumes            Low to moderate            Very low per part           Low (patient-specific)
                           production; long           number; many part           to moderate (standard
                           programmes                 numbers                     implants, dental)

Dominant risk Fatigue and fracture in Pressure, temperature, Patient safety; flight corrosion; safety and biocompatibility;

Dimension Aerospace Energy and oil & gas Medical

environmental sterility consequence

Who approves              OEM; aviation               Operator, OEM,              Medical device
                          authorities for certified   classification or           regulators; notified
                          products                    certification bodies        bodies where
                                                                                  applicable

Key frameworks            SAE AMS7000-series;         API 20S; DNV-ST-B203;       FDA AM guidance; ISO
                          OEM specifications;         operator specifications     13485; ISO 10993
                          NASA-STD-6030 for                                       series
                          spaceflight

Qualification burden      Very high for flight-       High; often part-by-        High; process
                          critical parts              part                        validation plus
                                                                                  regulatory clearance

Typical time to           Long                        Moderate for lower-         Long for new devices;
revenue                                               criticality parts; longer   shorter for some
                                                      for critical                guides and models

Commercial                OEM engineering and         Operator maintenance        Surgeons, hospitals,
gatekeeper                supply chain                and engineering teams       regulators and
                                                                                  reimbursement

Why success in one sector does not automatically transfer

It is tempting to assume that a supplier qualified for aerospace work can easily serve energy or medical customers. Some capabilities do transfer: process control discipline, metallurgical expertise, inspection capability and a culture of documentation. These are genuine advantages.

But much does not:

•   Materials differ. Aerospace titanium and nickel alloys overlap partly with energy materials, but
        sour-service alloys, implant-grade titanium and dental alloys each come with distinct
        specifications.

• Evidence differs. Fatigue data for an aerospace bracket does not demonstrate corrosion resistance in a subsea environment, or biocompatibility in the human body.

• Quality systems differ. An aerospace quality system such as AS9100 is not an ISO 13485 medical device quality system, and neither replaces an energy operator's supplier qualification.

• Buyers differ. Aerospace OEM supply-chain teams, oil and gas maintenance engineers and orthopaedic surgeons evaluate suppliers in completely different ways.

•   Economics differ. Aerospace may justify qualification over a production programme; energy may
        need to justify it part by part; medical may need to justify it through reimbursement and clinical
        adoption.

A supplier entering a new sector should therefore plan as if entering a new market, not just adding a new application.

What manufacturers should assess before pursuing each market

Before pursuing aerospace:

• Do we have, or can we achieve, the required quality system and customer approvals?

• Can we generate the material and process data the OEM will require, particularly fatigue data?

• Is there a specific programme or part family with enough volume to justify qualification?

• Can we sustain a multi-year qualification timeline financially?

Before pursuing energy and oil & gas:

• Which operators or OEMs have a defined AM qualification pathway, and which standards do they use?

• Can we identify parts with high downtime cost and a credible route to approval?

• Do we have the material testing and environmental performance data required?

• Who owns the design rights for the parts we would produce or reverse-engineer?

Before pursuing medical:

• Are we a contract manufacturer, a device developer, or both, and what regulatory responsibilities follow from that?

• Do we have, or can we build, an ISO 13485-aligned quality system and validated cleaning and sterilisation processes?

• Which regulatory pathway applies to the intended devices in each target market?

• Who is the clinical champion, and how will the device be reimbursed or purchased?

Conclusion: same technology, different businesses

Additive manufacturing gives aerospace, energy and medical companies access to the same fundamental capability: building complex parts directly from digital data. What each sector does with that capability, and what it demands in return, differs profoundly.

For manufacturers and technology vendors, the practical implication is focus. It is usually better to establish a strong, qualified position in one sector, understand its economics and gatekeepers thoroughly, and then expand deliberately, than to pursue all three at once with a capability that has been proven in none.

Omnidite Advisory works with technology and advanced manufacturing companies on application assessment and market entry, including evaluating which industrial sectors offer a credible path to adoption.

This article provides general information and commercial commentary, not legal, investment, regulatory, medical or certification advice. Illustrative examples and calculations are not actual customer engagements or quotations.